medigraphic.com
ISSN 1405-1710 (Print)

2013, Number 1

<< Back Next >>

Rev Cent Dermatol Pascua 2013; 22 (1)

Comorbidities in psoriasis

Maldonado GCA, Cardona HMA, Jurado SF

Language: Spanish
References: 39
Page: 15-21
PDF size: 115.25 Kb.


ABSTRACT

Psoriasis has conceptually evolved across time, from being considered a cutaneous disease on its first descriptions, to a «chronic inflammatory skin disease, without a defined etiology, genetically determined, physiopathology autoimmune, from intermittent evolution, with risk of cutaneous and systemic comorbidities, also psychological, that impacts on life quality». Patients with psoriasis have a bigger risk of presenting metabolic syndrome and diverse tumors, among other conditions. In this revision we summarize actual evidence about most frequent non-arthropathic comorbidities, arising on patients with psoriasis, and the importance of being opportunely diagnosed to provide a more adequate treatment and improve life quality.


REFERENCES

  1. Jurado F, Lizárraga C, Maldonado C, Aquino C. Psoriasis. En: Domínguez-Soto L, Saúl CA, editores. PAC Dermatología Parte C, Libro 3. México: Intersistemas, S.A. de C.V; 2011.

  2. Ávila D. ¿Qué es la comorbilidad? Trabajos de Revisión. Revista Chilena de Epilepsia 2007; 8: 49-51.

  3. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the Concepts of Disability, Frailty, Comorbidity: Implications for Improved Targeting and Care. J of Gerontol 2004; 59: 255-263.

  4. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. Journal of Chronic Diseases 1970; 23: 455-468.

  5. Bonavita V, De Simone R. Towards a definition of comorbidity in the light of clinical complexity. Neurol Sci 2008; 29: 99-102.

  6. Costello A, Erkanli A. Comorbidity. Journal of Child Psychology and Psychiatry 1999; 40: 57-87.

  7. Uher R, Heyman I, Mortimore C, Frampton I, Goodman R. Screening young people for obsessive-compulsive disorder. British Journal of Psychiatry 2007; 191: 353-354.

  8. Vena GA, Vestita M, Cassano N. Can early treatment with biologicals modify the natural history of comorbidities? Dermatologic Therapy 2010; 23: 181-193.

  9. Heidenreich R, Rocken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Path 2009; 90: 232-248.

  10. Shapiro J, Cohen A, David M, Hodak E, Chodik G, Viner A, Kremer E, Heymann A. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: A case-control study. J Am Acad Dermatol 2006; 56: 629-634.

  11. Mutairi N, Farag S, Mutairi A, Shiltawy M. Comorbidities associated with psoriasis: An experience from the Middle East. Journal of Dermatology 2010; 37: 146-155.

  12. Morowietz U, Elder J, Barrer J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006; 298: 309-319.

  13. Sommer D, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Fes 2006; 298: 321-328.

  14. Pietrzak A, Kadzielewski J, Janowski K, Rolinski J, Krasowska D et al. Lopoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity. Int J Dermatol 2009; 48: 379-387.

  15. Nisa N, Qazi M. Prevalence of metabolic syndrome in patients with psoriasis. Indian Journal of Dermatology, Venereology and Leprology 2010; 76: 662-665.

  16. Kremers H, McEvoy M, Dann F, Gabriel S. Heart disease in psoriasis. J Am Acad Dermatol 2007; 55: 347-354.

  17. Farkas A, Kemény L. Psoriasis and alcohol: is cutaneous ethanol one of the missing links? British Journal of Dermatology 2010; 162: 711-716.

  18. Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.

  19. Molin S, Jonckheere CL, Coates LC. The Second World Psoriasis and Psoriatic Arthritis Conference 2009: “Psoriasis – skin and beyond”. JEADV 2010; 24: 970-973.

  20. Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005; 5: 699-711.

  21. Eriksen KW, Woetmann A, Skov L et al. Deficient SOCS3 and SHP-1 Expression in Psoriatic T Cells. Journal of Investigative Dermatology 2010; 130: 1590-1597.

  22. Girolomoni G, Gisondi P. Psoriasis and systemic inflammation: underdiagnosed enthesopathy. JEADV 2009; 23: 3-8.

  23. Spâh F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. British Journal of Dermatology 2008; 159: 2-17.

  24. Coimbra S, Oliviera H, Reis F, Belo L, Figueiredo A, Teixeira F et al. Psoriasis and Cardiovascular Risk Factors a 12-week Follow-up study. Am J Clin Dermatol 2010; 11: 423-432.

  25. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-621.

  26. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230.

  27. Hamminga EA, Vander Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therap. Hed Hypotheses 2006; 67: 768-773.

  28. Herron MD, Hinckey M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1534.

  29. Neimann A, Shin D, Wang X, Margolis D, Tropel A, Gelfand J. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.

  30. Pietrzak A, Chodorowska G, Szepietowski J, Zalewska-Janowska A, Krasowska D, Hercogová J. Psoriasis and serum lipid abnormalities. Dermatologic Therapy 2010; 23(2): 160-173.

  31. Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and Dyslipidaemia: A population Study. Acta Derm Venereol 2008; 88: 561-565.

  32. Wolk K, Mallbris L, Larsson P, Rosebland A, Vingard E, Stahle M. Excessive Body Weight and Smoking Associates with a High Risk of Onset of Plaque Psoriasis. Acta Derm Venereol 2009; 89: 492-497.

  33. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005; 12: 295-300.

  34. Markuszeski L, Bissinger A, Janusz I, Narbutt J, Jedrzejowska A, Zalewska A. Heart rate an arrhythmia in patients with psoriasis vulgaris. Archives of Medical Research 2007; 38: 64-69.

  35. Gelfand J, Shin D, Meimann A, Wang S, Margolis D, Tropel A. There risk of lymphoma in patients with psoriasis. Journal of Investigative Dermatology 2006; 126: 2194-2201.

  36. Suzuki M, Hirano S, Ito H, Matsubara D, Kubota K, Takeda Y et al. Pulmonary lymphoma developed during long-term methotrexate therapy for psoriasis. Respirology 2007; 12: 774-776.

  37. Gupta M, Gupta A. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 2003; 4: 833-842.

  38. Kimball AB, Jacobson C, Weiss S, Vreeland MD, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383-392.

  39. De Korte J, Sprangers MAG, Mombers FMC, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Invest Dermatol 2004; 9: 140-147.




2020     |     www.medigraphic.com